VS 4718

Drug Overview

The medication known as VS 4718 is a highly specialized “Smart Drug” currently being developed to treat aggressive cancers. It is part of a new generation of targeted therapies that focus on the structural environment of a tumor. Rather than attacking all fast-growing cells like traditional chemotherapy, VS 4718 targets a specific protein that cancer cells use to move, survive, and resist treatment.

Here are the key details about this agent:

• Generic Name: VS 4718 (also known as PND-1186).
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Focal Adhesion Kinase (FAK) Inhibitor / Targeted Therapy.
• Route of Administration: Oral (taken by mouth as a tablet or capsule).
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is actively studied in advanced clinical trials for difficult-to-treat cancers.

What Is It and How Does It Work? (Mechanism of Action)

To understand VS 4718, it helps to think of a cancer cell as a traveler. To move through the body or survive in a new organ, the cell needs “anchors” to hold onto its surroundings. A protein called Focal Adhesion Kinase (FAK) acts as the control center for these anchors.

Targeted Inhibition

VS 4718 is a potent and selective inhibitor of the FAK protein. It works at the molecular level through several key steps:

1. Blocking the Anchor Signal: Once the drug enters a cancer cell, it binds to the FAK protein. This prevents FAK from sending signals that tell the cell it is safely attached to its environment.
2. Stopping the Spread: Without the FAK signal, the cancer cell loses its ability to “unstick” and “re-stick.” This makes it much harder for the cancer to move from the original tumor to other parts of the body (metastasis).
3. Breaking Resistance: One of the smartest things cancer does is build a thick “shield” of scar tissue (fibrosis) around itself to block chemotherapy. VS 4718 interferes with the signals that build this shield. By “softening” the tumor’s environment, it allows other chemotherapy drugs to reach the cancer cells more effectively.
4. Triggering Cell Death: In many aggressive cancers, FAK also sends survival signals. When VS 4718 blocks these signals, the cancer cell realizes it is no longer in a safe environment and may undergo a process of programmed self-destruction.

FDA-Approved Clinical Indications

Because VS 4718 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Pancreatic Cancer: Often used in combination with immunotherapy or chemotherapy to break through the dense tissue surrounding pancreatic tumors.
• Ovarian Cancer: Studied for its ability to treat tumors that have become resistant to standard platinum-based chemotherapy.
• Mesothelioma: Investigated for use in this aggressive form of lung-related cancer, often focusing on patients with specific genetic mutations (like NF2 loss).
• Advanced Solid Tumors: Used to see if new targeted combinations can stop the growth of various cancers that have spread throughout the body.

Non-oncological Uses:

• There are currently no non-oncological uses for VS 4718 in clinical development.

Dosage and Administration Protocols

Because VS 4718 is an investigational oral therapy, the dose is strictly managed by trial protocols. It is designed to be taken at home, which is much more convenient than hospital-based infusions.

Special Considerations

• Hepatic/Renal Insufficiency: Since the liver and kidneys process most oral targeted therapies, doctors monitor these organs weekly. If liver enzymes or kidney markers rise, the dose may be lowered or paused to ensure safety.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have focused on how VS 4718 can “prime” a tumor to make it easier to kill with other drugs.

• Overcoming Resistance: In trials for advanced ovarian cancer, adding a FAK inhibitor like VS 4718 to standard chemotherapy showed that some patients who had stopped responding to treatment saw their tumors stabilize or shrink again.
• Pancreatic Tumor Access: Research has shown that FAK inhibitors can reduce the “pressure” inside a pancreatic tumor by up to 30%. This allows standard chemotherapy to reach the center of the tumor much better than before.
• Immune Synergy: Studies using VS 4718 alongside immunotherapy (like PD-1 inhibitors) have shown a significant increase in the number of “fighting” T-cells that can enter the tumor.
• Safety Data: Numerical data from Phase 1 trials confirmed that the drug reached therapeutic levels in the blood without causing the severe, whole-body toxicity often seen with older chemotherapy.

Safety Profile and Side Effects

While VS 4718 is a targeted therapy, it can still cause side effects as the body adjusts to the medication.

Common Side Effects (>10%):

• Nausea and Diarrhea: The most common complaints, usually manageable with standard over-the-counter medicine.
• Fatigue: A general feeling of tiredness or low energy.
• Decreased Appetite: A temporary loss of interest in food.
• Headache: Mild to moderate head pain.

Serious Adverse Events:

• Liver Enzyme Elevation: The drug can put stress on the liver, which shows up in blood tests.
• Hematological Changes: A drop in red blood cells (anemia) or white blood cells, though this is less common than with standard chemo.
• Proteinuria: Small amounts of protein in the urine, which can be a sign of kidney stress.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent at this time.

Management Strategies:

• Liver Monitoring: Patients have blood drawn every 1 to 2 weeks to ensure liver enzymes stay in a safe range.
• Hydration: Drinking at least 8 glasses of water a day is recommended to protect the kidneys.
• Anti-Nausea Care: Doctors often prescribe “as needed” medicine for stomach upset to ensure patients can keep taking their daily doses.

Connection to Stem Cell and Regenerative Medicine

VS 4718 has a fascinating connection to Cancer Stem Cell research. Standard chemotherapy often kills the “adult” cancer cells but leaves behind “cancer stem cells.” These are the seeds that cause the cancer to come back later.

Research shows that the FAK protein is vital for the survival of these cancer stem cells. By using VS 4718, doctors hope to “kill the seeds” and prevent the cancer from regenerating. In regenerative medicine research, scientists are also studying FAK inhibitors to understand how healthy stem cells move, which could eventually lead to better treatments for wound healing or tissue repair.

Patient Management and Practical Recommendations

To ensure the best results and the highest safety, patients should follow a strict routine while taking VS 4718.

Pre-treatment Tests to be Performed:

• Comprehensive Metabolic Panel (CMP): To check baseline liver and kidney function.
• Complete Blood Count (CBC): To ensure blood levels are healthy before starting.
• Tumor Biopsy: Occasionally, a sample is taken to see if the tumor has high levels of FAK protein.

Precautions During Treatment:

• Contraception: This drug can be harmful to an unborn baby. Both men and women must use highly effective birth control during and for several months after treatment.
• Infection Control: While rare, if your white blood cell count drops, you should avoid large crowds and people who are visibly sick.

“Do’s and Don’ts” List:

• DO take your pills at the same time every day to keep a steady amount in your blood.
• DO report any yellowing of the skin or eyes (jaundice) to your doctor immediately.
• DON’T take any new herbal supplements (like St. John’s Wort) without asking your oncologist, as they can stop the drug from working.
• DON’T stop taking the medication just because you feel better; the full cycle is necessary to kill the cancer stem cells.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. VS 4718 is an investigational targeted agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.